Navigation Links
European Neurologists Expect Significant Increases in the Use of Both Tysabri and Extavia in Their Multiple Sclerosis Patients the Next Six Months, According to a Recent Report From BioTrends
Date:12/21/2010

EXTON, Pa., Dec. 21, 2010 /PRNewswire/ -- BioTrends Research Group, Inc. finds that while neurologists in the EU tend to prescribe the established interferon betas as their first line disease modifying agents (DMAs) for the treatment of multiple sclerosis (MS) patients, they are most satisfied with Biogen/Elan's Tysabri. Prescribing of both Tysabri and Novartis's recently launched DMA, Extavia, is anticipated to increase over the next six months with Bayer's Betaferon suffering the most in terms of market share loss. Despite these expected changes, neurologists clearly associate most of the DMAs with a certain MS patient type and their reported prescribing reflects these preference patterns.

The recently released TreatmentTrends®: Multiple Sclerosis in the European Union report finds that neurologists in the U.K. have less clinical experience with many of the DMAs, prescribe DMAs to a smaller percentage of their MS patients, and are detailed less than their counterparts in France, Germany, Italy and Spain. In line with these regional differences, neurologists in the U.K. report relying on different attributes when making their DMA prescribing decisions and identify different unmet needs for DMAs in development compared to neurologists from the other EU regions.

Among the eight therapies in development that were profiled in the research, interest is rated highest for Novartis's Gilenya and Merck Serono's Movectro -- despite the recent nonapproval by the European Medicines Agency for the latter product which Merck has recently appealed. Neurologists in the U.K. again diverge in their reported interest in the DMAs in development with a greater level of enthusiasm for Genzyme/Bayer's alemtuzumab compared to their counterparts in the other EU regions. While familiarity and interest is currently low for Biogen's PEG-Avonex and BG-12, Teva's laquinimod, Sanofi-Aventis's teriflunomide and Abbott/Biogen's daclizumab, for some of these DMAs in de
'/>"/>

SOURCE BioTrends Research Group, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
2. Boston Scientific Announces Schedule for European Society of Cardiology Congress 2007
3. European Experts Recommend Pregnant and Nursing Women Take More DHA - Every Day
4. Genasense(R) Data in Melanoma to be Presented in Opening Session at First Worldwide Melanoma Center Meeting of the European Association of Dermato-Oncology
5. Terumo Heart to Announce Results of European Clinical Trial of DuraHeart(TM) LVAS at European Association of Cardiothoracic Surgeons Meeting in September
6. Threshold Pharmaceuticals Announces Two Presentations on Glufosfamide at the 2007 European Cancer Conference (ECCO)
7. Study Results for Aclidinium Bromide, a Novel Anticholinergic, Presented at European Respiratory Society Annual Congress
8. Life Recovery Systems Receives European CE Mark Approval for Its ThermoSuit(R) System
9. Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
10. European Unions CHMP Issues Positive Opinion on PEGINTRON(TM) Combination Therapy for Retreating Hepatitis C Patients Who Failed Previous Therapy
11. Positive Xeloda(R) Five-Year Overall Survival Study Data in the Adjuvant Treatment of Colon Cancer Presented at Leading European Cancer Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... -- CVS Caremark Corporation (NYSE: CVS ) announced ... payable in connection with its previously announced cash tender offers ... any and all of its 6.250% Senior Notes due 2027 ... maximum amount of its 6.125% Senior Notes due 2039, 5.750% ... (collectively, the "Maximum Tender Offer Notes" and together with the ...
(Date:8/21/2014)... , Aug. 21, 2014 /CNW/ - Bedrocan Cannabis ... three independent members to its Board of Directors, ... experience of the company, a leading licensed producer ... . Internationally, Bedrocan has 13 years, experience in ... in seven countries, including Canada. ...
(Date:8/21/2014)... 2014  SI-BONE, Inc. ( San Jose, California ... use of the iFuse Implant System, ® a ... the sacroiliac (SI) joint, announced that Priority Health ( ... Lumbar Fusion Medical Policy No. 91590-R4 providing positive coverage ... states that the fusion procedure, which employs the iFuse ...
Breaking Medicine Technology:CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 2CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 3CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 4CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 5CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 6Senior Life Sciences Executives Join Bedrocan as Independent Directors 2Senior Life Sciences Executives Join Bedrocan as Independent Directors 3SI-BONE, Inc. Announces Positive Coverage Decision by Priority Health 2SI-BONE, Inc. Announces Positive Coverage Decision by Priority Health 3
(Date:8/22/2014)... August 22, 2014 Dealing with a drug ... when the addict is a child. Adolescent substance abuse has ... a long time. But a new helpline is now providing ... professional youth rehab for something like a teen drug ... designed to help make a positive impact in the community. ...
(Date:8/22/2014)... August 22, 2014 According to ... System and Adaptive Cruise Control (ACC) System Market ... Forecasts 2014 - 2019", published by MarketsandMarkets, classifies ... Market in terms of volume and value. The ... years as well as covers review of the ...
(Date:8/21/2014)... August 22, 2014 The natural loss of ... lines, wrinkles and sagging of skin. Using products to ... age 40, the body has lost about 15% of it ... 45%," says Kathy Heshelow, founder of Sublime Beauty®. "Collagen ... it - well, we know what happens." , Collagen in ...
(Date:8/21/2014)... (PRWEB) August 21, 2014 Local agencies ... have larger discounts for specific protection plans, according to ... helping consumers to quote life insurance from local agencies ... The local agents that appear inside of the national ... fast method of price reviews this year. Adults who ...
(Date:8/21/2014)... (PRWEB) August 21, 2014 AVEC ... to announce the addition of Kerry Gillespie as ... of healthcare management experience, Gillespie brings an extremely ... multiple executive management positions with prominent industry leading ... served as President of Triad Isotopes, Inc. a ...
Breaking Medicine News(10 mins):Health News:Cincinnati’s New Troubled Teen Helpline is Making a Difference in the Community 2Health News:Automotive Blind Spot Detection System Market Worth $2.8 Billion and Automotive Adaptive Cruise Control System Market Worth $6.1 Billion by 2019 – New Report 2Health News:Automotive Blind Spot Detection System Market Worth $2.8 Billion and Automotive Adaptive Cruise Control System Market Worth $6.1 Billion by 2019 – New Report 3Health News:Automotive Blind Spot Detection System Market Worth $2.8 Billion and Automotive Adaptive Cruise Control System Market Worth $6.1 Billion by 2019 – New Report 4Health News:4 Skincare Products That Boost and Nurture Collagen on Sale at Sublime Beauty® 2Health News:4 Skincare Products That Boost and Nurture Collagen on Sale at Sublime Beauty® 3Health News:Life Insurance from Local Agents Now Priced Nationally Through Complimentary Tool Online 2Health News:Kerry Gillespie Appointed as Chief Executive Officer of AVEC Health Solutions 2
... campuses of the University of California has found that flash-heating ... virus. ,The researchers hope that this technique - ... pan of water over a flame or single burner - ... nations will soon be able to more safely feed their ...
... rigorous U.S. trial comparing two traditional operations for stress ... urologists and urogynecologists supported by the National Institutes of ... more women achieve dryness than the Burch technique. ... a meticulous, relatively long-term comparison of these common surgeries ...
... given people another reason to quit smoking, by finding that ... depression in comparison to those who never smoke. ,The ... an elevated risk of depressive symptoms in short run, this ... long run. ,In other words, both completely ...
... Well, it doesnt have to be that way ... say that they have successfully managed to reduce ... containing vitamin A. ,Not only did the ... 23 people revealed it boosted levels of important skin ...
... a condition that most people prefer not to talk about, ... this embarrassing problem. It's called overactive bladder (OAB) and ... sometimes causing urine leakage. ,Now, to reduce the ... using nerve stimulation in the ankle to better help control ...
... chronic gum disease periodontitis, may have an increased risk of ... ,Periodontitis is an oral infection thought to be caused by ... well. ,The study was conducted by a team ... of New York at Buffalo and the Roswell Park Cancer ...
Cached Medicine News:Health News:Flash-heating Inactivates HIV in Breast Milk: Study 2Health News:Flash-heating Inactivates HIV in Breast Milk: Study 3Health News:Sling Surgery Better Than Burch for Treating Stress Incontinence in Women 2Health News:Sling Surgery Better Than Burch for Treating Stress Incontinence in Women 3Health News:Regular Smokers are at the Risk of Developing Depression 2Health News:Wrinkles can Be Really Ironed Out, Thanks to Vitamin A 2Health News:Stimulating the Ankle Can Help Patients With Overactive Bladder 2Health News:Men With Chronic Gum Disease at Higher Risk of Tongue Cancer 2
... take the words "mobile operating table" literally! The ... important functions of a general purpose operating table ... For table operations, a cable connected hand control, ... available. Plus, there is a control panel at ...
... carbon fiber c-arm table allows 50 ... brachytherapy, gynecology, gastroenterology, cardiovascular, orthopedic, ENT, ... design allows easy access for all ... 16-inch elevating travel, 16-inch longitudinal travel, ...
... for procedures where stability, access, and ... A cantilevered low attenuation carbon fiber ... The radiolucent area is free of ... and unobstructed C-Arm positioning. Functional design ...
... Lyphochek Elevated Immunosuppressant Control is a bilevel ... blood. This unique product is ideal for ... high Cyclosporine levels, such as C2 monitoring, ... at two hours post-dose., ,Lyphochek Elevated Immunosuppressant ...
Medicine Products: